Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for severe combined immunodeficiencies.

H Bobby Gaspar1, Adrian J Thrasher

  • 1Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. h.gaspar@ich.ucl.ac.uk

Expert Opinion on Biological Therapy
|August 27, 2005
PubMed
Summary

Severe combined immune deficiencies (SCIDs) are fatal genetic disorders. Gene therapy offers a promising alternative to transplantation, correcting immune defects but requiring careful safety monitoring for potential side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic activity of a hematopoietic stem cell-delivered cell-penetrating frataxin in Friedreich's ataxia models.

Cell reports. Medicine·2026
Same author

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Advances in Gene Therapy for Inherited Haemoglobinopathies.

Hematology reports·2026
Same author

Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.

Blood·2026
Same author

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Obstetrical & gynecological survey·2025
Same author

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Obstetrical & gynecological survey·2025

Area of Science:

  • Immunology
  • Genetics
  • Pediatric Hematology/Oncology

Background:

  • Severe combined immune deficiencies (SCIDs) are monogenic diseases causing severe lymphocyte defects and life-threatening infections.
  • Infants with SCID typically do not survive the first year without treatment.
  • Hematopoietic stem cell transplantation is a primary treatment, but matched donors are scarce, and haploidentical transplants have higher complication rates.

Purpose of the Study:

  • To evaluate gene therapy as an alternative treatment for SCID.
  • To assess the efficacy and safety of ex vivo gene transfer for immune defect correction.

Main Methods:

  • Correction of genetic defects using retroviral gene delivery in hematopoietic progenitor cells.
  • Clinical trials involving ex vivo gene transfer for SCID-X1 and ADA-SCID.

Related Experiment Videos

Main Results:

  • Gene therapy demonstrated effective immune recovery in SCID patients.
  • Successful correction of immune defects was achieved, offering an alternative to transplantation.

Conclusions:

  • Gene therapy is a viable alternative to transplantation for certain SCIDs.
  • Insertional mutagenesis from retroviral vectors has led to leukemia in some SCID-X1 patients, necessitating further research into safer vector systems.